Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance. For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic buyout, a 7% dividend yield backed by a reaffirmed outlook, and a restructuring story with multiple near-term FDA catalysts. That is a lot of optionality for very little share price.
With that in mind, here are three healthcare stocks trading under $30 that look attractively priced heading into the back half of 2026.
Kenvue (NYSE: KVUE)
Kenvue (NYSE:KVUE | KVUE Price Prediction) is the consumer health company spun off from Johnson & Johnson (NYSE:JNJ), home to Tylenol, Neutrogena, Aveeno, Listerine, BAND-AID, Zyrtec, and Nicorette. Shares closed the last session at $19.83, comfortably under the $30 ceiling and up 17.65% year to date, which still leaves the stock below its 52-week high of $21.85.
The fundamentals are firming quickly. Q1 FY26 delivered adjusted EPS of $0.32 versus $0.26 expected, a 23.08% beat, on revenue of $3.91 billion, up 4.49% year over year. Gross margin expanded 90 basis points to 58.9% and adjusted operating margin reached 24.0%, while free cash flow climbed 60.64% to $400 million. Kenvue carries a forward P/E of 17 and a 4.28% dividend yield, with an analyst consensus price target of $19.50.
The bull case is anchored by the pending acquisition by Kimberly-Clark (NYSE:KMB), structured as $3.50 cash per share plus 0.14625 Kimberly-Clark shares, expected to close in the second half of 2026 with shareholder approval already secured and the HSR waiting period expired. That gives holders a defined takeout floor while the underlying business keeps expanding margins. CEO Kirk Perry said the company is “confident in our ability to navigate ongoing macro uncertainty” as it works toward closing the combination.
The key risk is deal execution: foreign regulatory approvals could delay the timeline, and total debt has risen to $8.7 billion. Even so, with a takeout premium, margin momentum, and defensive brands, Kenvue looks like a low-volatility way to earn a return under $20. Pfizer (NYSE:PFE) is one such name.
Pfizer (NYSE: PFE)
Pfizer is one of the largest global biopharmaceutical companies, with a portfolio spanning oncology, vaccines, specialty care, and primary care. The stock last traded at $24.32, up just 0.97% year to date, keeping it well inside the under-$30 zone and near the low end of its $21.97 to $28.28 52-week range.
At current levels, Pfizer trades at a trailing P/E of 19 and a forward P/E of 8, with a dividend yield of 7.2% supported by a quarterly payout of $0.43 that has held steady since Q1 2025. Q1 FY26 marked the fifth consecutive EPS beat, with adjusted EPS of $0.75 versus $0.72 expected on revenue of $14.45 billion, up 5.4% year over year. Growth drivers included Padcev +39%, Nurtec ODT/Vydura +41%, Eliquis +13%, and Abrysvo +37%. The analyst consensus price target sits at $29.15, with 11 buy or strong buy ratings against 16 holds.
The bull case rests on three pillars. First, the Vyndamax patent settlement extends U.S. exclusivity to June 2031, removing a major overhang on one of the company’s most profitable franchises. Second, management reaffirmed FY26 guidance of $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted EPS. Third, the pipeline is loaded, with roughly 20 key pivotal trial starts planned in 2026, including 10 obesity assets from the Metsera acquisition. CEO Albert Bourla said Pfizer is “particularly encouraged by what we’re seeing in oncology and obesity.”
The risk profile is real. Pfizer faces a $1.5 billion expected revenue headwind from generics and biosimilars in 2026, ongoing COVID product declines (Comirnaty -59%, Paxlovid -63%), and pricing pressure from Most Favored Nation policy discussions. On Polymarket, traders currently give a 13% implied probability that the U.S. federal government takes a stake in Pfizer this year, a low-odds tail risk worth acknowledging. For income-oriented value investors, Pfizer offers a rare combination of a 7% yield, single-digit forward multiple, and a rebuilding growth story.
Viatris (NASDAQ: VTRS)
Viatris (NASDAQ:VTRS) is a global pharmaceutical company blending generics and branded drugs, including Lipitor, Lyrica, EpiPen, Viagra, and Creon. Shares last changed hands at $16.70, up a remarkable 36.24% year to date and 85.74% over the past year, yet still trading materially below the $30 ceiling.
Even after the rally, valuation remains compressed. Viatris trades at a forward P/E of 7, a price-to-book of 1.327, and offers a 2.97% dividend yield from a $0.12 quarterly payout that has held steady for 16 consecutive quarters. Q1 FY26 delivered adjusted EPS of $0.59 versus $0.50 expected, a 17.53% beat, on revenue of $3.52 billion, up 8.1% year over year. Greater China net sales surged 22% to $680.1 million, brands grew 10% to $2.33 billion, and adjusted EBITDA rose 14% to $1.05 billion. The analyst consensus target of $17.81 is now within striking distance.
The bull case combines cost discipline with catalysts. Management is executing an enterprise-wide restructuring targeting $600 to $700 million in annualized cost savings with up to a 10% workforce reduction, and reaffirmed FY26 guidance of $14.45 to $14.95 billion in revenue, $2.33 to $2.47 in adjusted EPS, and $1.95 to $2.35 billion in free cash flow. The pipeline offers three near-term decisions: the contraceptive patch PDUFA on July 30, 2026, the MR-141 presbyopia PDUFA on October 17, 2026, and the non-opioid pain therapy MR-107A-02 decision expected December 27, 2026. CEO Scott Smith said the company is “well positioned to deliver on our full-year guidance.”
The risks are meaningful. Viatris posted a FY25 GAAP net loss of $3.51 billion including $2.9 billion in Q1 25 goodwill impairment, and continues to work through the Indore FDA warning letter and a $71.9 million writedown tied to the Nashik India facility fire. Generic pricing pressure in North America and Japan remains a persistent headwind. Still, with a mid-single-digit forward multiple, reaffirmed guidance, and three catalysts before year-end, Viatris looks like the highest-optionality name of the three.
The Bottom Line
Kenvue, Pfizer, and Viatris each carry real risks, from deal timing and regulatory hurdles to patent cliffs, pricing policy, and manufacturing issues. What makes them interesting today is that their sub-$30 quotes come attached to reaffirmed 2026 guidance, expanding margins, and identifiable catalysts, not just cheap headline multiples. Investors should dig into the filings, weigh each risk against their own time horizon, and decide whether the setup matches their portfolio needs before acting.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks